Q-Line BiotechNSE:QLINE -5.15%12 EBITDA Margin % is 20.65% as of Mar. 2025, which is 4% above its 10-year median of 19.85. GuruFocus rates NSE:QLINE with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Q-Line Biotech ranks better than 77.08% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Q-Line Biotech's EBITDA for the
six
months ended in Mar. 2025 was ₹648 Mil. Q-Line Biotech's Revenue for the
six
months ended in Mar. 2025 was ₹3,138 Mil. Therefore, Q-Line Biotech's EBITDA margin for the quarter that ended in Mar. 2025 was 20.65%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Q-Line Biotech EBITDA Margin % Related Terms
Q-Line Biotech EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Q-Line Biotech's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Q-Line Biotech EBITDA Margin % Chart
Q-Line Biotech Annual Data
Trend
Mar23
Mar24
Mar25
EBITDA Margin %
19.18
19.85
20.65
Q-Line Biotech Semi-Annual Data
Mar23
Mar24
Mar25
EBITDA Margin %
19.18
19.85
20.65
NSE:QLINE vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Q-Line Biotech's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Q-Line Biotech EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Q-Line Biotech's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Q-Line Biotech's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Q-Line Biotech (NSE:QLINE) has a EBITDA Margin % of 20.65% as of Mar. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Q-Line Biotech and its competitors. This is near median its historical median of 19.85. Over the past decade, Q-Line Biotech's EBITDA Margin % has ranged from 19.18 to 20.65. According to the industry distribution chart, Q-Line Biotech ranks #187 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 22.9%.
Is Q-Line Biotech's EBITDA Margin % too high?
Q-Line Biotech's current EBITDA Margin % of 20.65% is near median its 10-year median of 19.85. Over the past 10 years, this metric has ranged from a low of 19.18 to a high of 20.65. The Medical Devices & Instruments industry median EBITDA Margin % is 7.39. Q-Line Biotech's value of 20.65% is 179.6% above this industry median. Based on the distribution chart, Q-Line Biotech ranks #187 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Q-Line Biotech has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Q-Line Biotech's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Q-Line Biotech ranks #187 out of 816 companies for EBITDA Margin %. This places Q-Line Biotech in the top 23% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.39. Q-Line Biotech's value of 20.65% is 179.6% above this benchmark. Historically, Q-Line Biotech's own EBITDA Margin % has ranged from 19.18 to 20.65 over the past decade. While the company's 10-year median is 19.85 vs. the industry median of 7.39, Q-Line Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.39, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Q-Line Biotech's current EBITDA Margin % of 20.65% is 179.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Q-Line Biotech and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Q-Line Biotech's current EBITDA Margin % is 20.65%, which is near median its own 10-year median of 19.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-Line Biotech stock overvalued right now?
Q-Line Biotech (NSE:QLINE) has a current EBITDA Margin % of 20.65%. The current EBITDA Margin % is 20.65%, which is near median its 10-year median of 19.85 and 179.6% above the Medical Devices & Instruments industry median of 7.39. Q-Line Biotech's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Q-Line Biotech (NSE:QLINE), the current EBITDA Margin % is 20.65% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Q-Line Biotech Ltd is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs directly or through its distributors majorly to diagnostic service providers, hospitals and medical colleges. It is engaged in Manufacturing and Trading into Biochemistry Regnant, Instruments and Consumables. The majority of revenue is derived from the Manufacturing segment.
12GF Score
Get the complete analysis for NSE:QLINE
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:QLINE has been successfully added to your 